Tourmaline Bio (TRML) Expected to Announce Earnings on Thursday

Key Points

• Tourmaline Bio (NASDAQ:TRML) is set to announce its Q2 2025 earnings on Thursday, August 14th, with analysts predicting a loss of ($0.95) per share.
• The company's stock is currently priced at $21.94, with a 12-month low of $11.56 and a high of $29.79, reflecting a market cap of $563.42 million.
• Analysts have a consensus rating of "Buy" for Tourmaline Bio, with target prices ranging from $50.00 to $70.00 based on recent reports from HC Wainwright and Chardan Capital.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect Tourmaline Bio to post earnings of ($0.95) per share for the quarter.

Tourmaline Bio Trading Down 2.1%

TRML opened at $21.94 on Thursday. Tourmaline Bio has a 12 month low of $11.56 and a 12 month high of $29.79. The business's 50-day moving average price is $18.53 and its 200-day moving average price is $16.36. The company has a market cap of $563.42 million, a P/E ratio of -6.83 and a beta of 2.04.

Analyst Ratings Changes

TRML has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Tourmaline Bio in a report on Monday, May 5th. Chardan Capital reiterated a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a report on Monday, May 5th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $49.33.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.